Influence of SCENAR-therapy on the pregnancy course, labor, state of a neonate and a first-year infant in women with noncarryi

We investigated effectiveness of SCENAR-therapy in complex treatment of 60 pregnant women with urogenital infections at 16–18 weeks of pregnancy. The control group included 50 pregnant women with similar urogenital infections that underwent conventional antibacterial and antiviral therapy after 16–18 weeks of pregnancy. Using SCENAR-therapy in treating pregnant women with miscarriage of infectious genesis significantly improves prognosis of bearing a child, the state of a fetus, neonate and a first-year child, decreased the incidence and severity of placental inflammatory processes and intrauterine infection. Miscarriage is not only current medical concern, but also a serious social-economic problem with the case rate 15-20% among all desirable pregnancies. Today urogenital infection is one of the major causes of miscarriage, which may have harmful effect on the course of the pregnancy, state of a fetus and a neonate. Infectious pathology is mainly caused by genital microplasmas, clamydia, herpes simplex virus (HSV) and cytomegalovirus (CMV) [5, 7, 12]. New conditions for infection development are created during gestation. It is connected with general and local immunity peculiarities of pregnant women. Systemic gestational immunosuppression (suppression of inflammatory TH-1-immune response route) in healthy women provides